Logo

Zogenix Presents Results of Fintepla's (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients- Caregivers- and Families at AAN 2021

Share this
Zogenix Presents Results of Fintepla's (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients- Caregivers- and Families at AAN 2021

Zogenix Presents Results of Fintepla's (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients- Caregivers- and Families at AAN 2021

Shots:

  • The P-III study is designed to assess caregivers’ perspectives on the long-term seizure & non-seizure-related benefits of Fintepla on patients with Dravet syndrome and on their caregivers and families
  • Results: seizure-related benefits noted by caregivers include a reduction in frequency- seizure activity- and shorter recovery time while non-seizure benefits include improvements in executive functions such as cognition (76%)- learning- problem-solving (56%)- mood (41%)- sleep quality (47%)- motor function (46%) and speech (48%)
  • The caregivers themselves felt less stress (66%) anxiety- and depression (68%)- with 62% of employed parents missing less work- sleep improved (71%). Family benefits showed improvement in behavior and/or mood of siblings (58%)

  Ref: GlobeNewswire | Image: Zogenix

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions